mCODE: Improving data sharing to enhance cancer careMarch 12, 2021Patient & Survivor CareBreast CancerCNS/Brain CancerGastrointestinal CancerGenitourinary CancerGynecologic CancerHead & Neck/Thyroid Cancers
Bladder cancer indication withdrawn for durvalumabMarch 1, 2021Genitourinary CancerGynecologic Cancer
Enfortumab vedotin shows promise as new option for urothelial carcinomaMarch 1, 2021Genitourinary Cancer
Enfortumab vedotin offers hope to poor-prognosis patients with advanced urothelial cancerFebruary 26, 2021Genitourinary Cancer
Surveillance after testicular cancer: New approaches slash radiation exposureFebruary 25, 2021Genitourinary Cancer
How has the pandemic affected rural and urban cancer patients?February 18, 2021Patient & Survivor CareBreast CancerCNS/Brain CancerCOVID-19 UpdatesGastrointestinal CancerGenitourinary CancerGynecologic Cancer
Combo delivers ‘impressive’ survival results in first-line RCC settingFebruary 17, 2021Genitourinary CancerRenal Cell Carcinoma
Cabozantinib could be new standard for papillary RCCFebruary 16, 2021Genitourinary CancerRenal Cell Carcinoma
CCR score can guide treatment decisions after radiation in prostate cancerFebruary 13, 2021Genitourinary Cancer
Liquid vs. tissue biopsy in advanced prostate cancer: Why not both?February 12, 2021Genitourinary CancerLOTME
Declines in PSA screening may account for rise in metastatic prostate cancersFebruary 12, 2021Genitourinary Cancer
